Media Contacts
photo:Tulchan  Communications
Tulchan Communications
Tom Buchanan
020 7353 4200
Tulchan Communications
Victoria Huxster
020 7353 4200
Tulchan Communications
Matt Low
020 7353 4200
Share this release
Share on: Twitter
Share on: Facebook
Share on: LinkedIn
Latest news
York,
11
May
2015
|
08:29
Europe/Amsterdam

Tissue Regenix Group plc Further Medicare Coverage Approval for DermaPure®

Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, today announces it has secured approval from CGS Medicare for coverage of DermaPure® reimbursement. CGS covers the states of Ohio and Kentucky and adds a further 1.9m Medicare beneficiaries who can now receive the outstanding clinical benefits of the product.

Tissue Regenix launched DermaPure® in 2014 and has since made significant progress in not only demonstrating the clinical benefits but also securing reimbursement for it. In March we announced that DermaPure® had been approved for reimbursement from the Novitas administrator and the combination of this and CGS means that DermaPure® is now available to 10.8 million Medicare beneficiaries across 14 states.

Today’s announcement is evidence of the growing momentum behind the product but also is further validation of TR’s ability to deploy its technology commercially.

Antony Odell, CEO of Tissue Regenix
“We welcome CGS’ decision to provide coverage in what is an important additional step in achieving our strategic objective of full commercialisation of DermaPure® in the United States. We continue to work hard to raise awareness of the product based on the strong clinical outcomes for patients and we are delighted to get CGS coverage so soon after Novitas in March.”
Antony Odell, CEO of Tissue Regenix